The freshest thing on the table today is a small study comparing two very different substances head to head. Researchers tested a high dose of THC — the part of cannabis that gets people high — against psilocybin, the active ingredient in so-called magic mushrooms. Early signs suggest psilocybin produced far deeper, more meaningful experiences for the people in the study than THC did. The stock market, meanwhile, barely moved. The main companies in this space — Compass Pathways and atai — shifted by less than half a percent. In Washington, several bills meant to help veterans, including ones about housing, are inching forward. But none of them carry a provision that would give veterans legal access to psychedelic therapy. That absence is the quiet story of the day.
Beneath the surface, a pattern is holding firm. Real approval for these medicines does not come from an enthusiastic official or a popular podcast appearance. It comes through a slow, careful process: solid trial data first, then a formal recommendation from health authorities, then rulemaking that can take years. Even a new FDA leader who personally believes in psychedelics cannot skip those steps. And the drug-scheduling system — the government's ranking of how restricted a substance is — sits partly with a separate agency, the DEA, which moves at its own pace. So the tiny stock moves make sense. The excitement is already priced in. Nothing will truly move these companies until a real, dated result from a large final-stage trial arrives. That is the honest read: direction is unclear until the next real result lands. The deeper current, though, is that the science is quietly sharpening. The THC-versus-psilocybin study is a small sign of researchers learning to tell exactly what each medicine does and does not do — and that precision is what will eventually win trust.
For the people inside this story, the waiting is the hardest part. A veteran carrying trauma that ordinary treatments have not touched watches these housing and benefits bills advance, and feels the sting of what is missing — again — from the fine print. A family hoping a loved one might one day try psilocybin for depression reads that the science is careful, and careful feels slow when you are hurting now. But careful is also what makes a treatment last. The highest thing genuinely possible right now is not a sudden breakthrough. It is trust being built brick by brick, so that when access finally comes, it comes to stay — safe, legal, and real. That day is closer than it was, even on a quiet Thursday.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
The medicine is older than the fear. The healing is older than the wound.
75%
No official rescheduling of psilocybin, MDMA, or ibogaine this year
Even though the new head of the FDA (the US drug regulator) publicly supports psychedelic medicines, actually moving these drugs to a less restricted legal category takes years of formal government steps — it requires sign-off from the Department of Health and Human Services plus a lengthy public rulemaking process. Talking favorably about psychedelics on a podcast does not skip any of those steps. Nothing changes on paper in 2026.
→ Supportive rhetoric at the FDA does not equal legal change — rescheduling these drugs is a multi-year bureaucratic process that will not finish in 2026.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
No DEA rescheduling action on psilocybin, MDMA, or ibogaine occurs despite the new FDA pick's advocacy.. Scheduling requires an HHS recommendation plus rulemaking — a multi-year process. A podcast-friendly appointee doesn't shortcut Controlled Substances Act procedure.
70%
Spravato's label and safety rules stay unchanged despite political pressure
Spravato (the brand name for esketamine, a nasal spray related to ketamine used for hard-to-treat depression) currently comes with strict safety requirements — patients can only use it under medical supervision in a clinic. There's political pressure to loosen those rules, but changing a drug's official label or safety program requires submitting new scientific data to the FDA, not just lobbying. A major clinical trial being run in Brazil on this question won't produce US-applicable results fast enough to matter in 2026.
→ Political pressure alone cannot change Spravato's safety rules — new data must be reviewed first, and that process won't finish in 2026.
Resolves: 2026-12-31 · USA
REGULATORY
the precise call ▾
The new FDA leadership issues no esketamine (Spravato) label or REMS modification before year-end despite political pressure.. Label changes require data packages, not political will. The Brazilian SAVE esketamine suicide trial is external and won't move a US REMS this fast.
72%
Veteran housing bills move forward with no psychedelic therapy add-on
Two bills aimed at helping veterans — the Housing for All Veterans Act and the BUFFER Act — are making their way through congressional committees. Advocates have tried to attach provisions that would give veterans access to psychedelic-assisted therapy, but those additions are not making the cut. This matters because veterans are one of the most compelling patient groups for psychedelic treatments, yet the legislative path keeps closing on them.
→ Veterans' bills keep moving without any psychedelic therapy access attached, leaving that door firmly closed for now.
Resolves: 2026-11-30 · Global
LEGISLATION
the precise call ▾
The Housing for All Veterans Act and BUFFER Act advance in committee this cycle with no psychedelic-therapy access provision attached.. These are housing/benefits vehicles. Every cycle veteran-adjacent bills move without the psychedelic amendment we push for. Pattern holds painfully.
70%
Veteran bills pass committee again with no psychedelic therapy clause
This is the same pattern playing out again: legislation that helps veterans with housing and benefits advances in Congress, but every attempt to slip in a clause giving veterans legal access to psychedelic-assisted therapy gets left out. Multiple independent expert analyses agree on this outcome. It matters because veterans with PTSD (post-traumatic stress disorder) and depression are among the people most likely to benefit from these treatments.
→ Experts across the board agree: veteran bills will move forward this year without any psychedelic therapy provision attached.
Resolves: 2027-02-23 · Global
LEGISLATION
the precise call ▾
Veteran housing/BUFFER bills advance this cycle with no psychedelic-access provision attached.. Consensus of 3 agents: veterans_advocate, legislator, fda_reviewer. 0 dissenting.
70%
Two major psychedelic company stocks stay flat without a trial result
Shares of COMPASS Pathways (ticker: CMPS) and ATAI Life Sciences (ticker: ATAI), two prominent publicly traded psychedelic drug companies, are predicted to move less than 10% in either direction from where they sit today. The reason: any big news that could move the stock — like results from a large Phase 3 (final stage) clinical trial of their lead psilocybin drug COMP360, or a merger deal — is not scheduled to happen imminently. The market has already priced in the current story.
→ COMPASS and ATAI stocks will likely go nowhere fast until a major clinical trial result or merger deal is officially announced.
Resolves: 2026-10-15 · Global
CAPITAL-MARKETS
the precise call ▾
CMPS and ATAI remain within ±10% of today's close absent a dated Phase 3 psilocybin readout announcement.. Today's <0.5% moves show narrative is fully priced. Only a scheduled COMP360 readout or M&A term sheet moves these names — neither is on today's calendar.